Literature DB >> 8203842

Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.

G P Voorn1, J Kuyvenhoven, W H Goessens, W C Schmal-Bauer, P H Broeders, J Thompson, M F Michel.   

Abstract

The role of Staphylococcus aureus tolerance in the treatment and prophylaxis of endocarditis in rats was investigated. The efficacies of vancomycin, teicoplanin, and daptomycin, alone and in combination with rifampin, were compared in rats with endocarditis infected with a tolerant strain of S. aureus and in rats with endocarditis infected with its nontolerant variant. In vitro the cloxacillin-tolerant strain was also tolerant to vancomycin and teicoplanin, but not to daptomycin. However, tolerance to these antibiotics did not influence the results of treatment of experimental S. aureus endocarditis. There was no difference in the bacterial densities in the vegetations of rats infected with either the tolerant or the nontolerant strain after 5 days of treatment with any of the antibiotic regimens. Of all antibiotics, daptomycin was the most effective in reducing bacterial numbers in vegetations. Combination of rifampin with vancomycin or teicoplanin improved the results of treatment for the tolerant as well as the nontolerant strains. Daptomycin was as effective alone as in combination with rifampin. In contrast, tolerance influenced the prophylactic effects of vancomycin and teicoplanin. The proportion of rats with sterile vegetations after prophylaxis with vancomycin or teicoplanin at a low dose was lower for those infected with the tolerant strain than for those infected with the nontolerant strain. A low dose of daptomycin was equally effective against the tolerant and the nontolerant strains. However, higher doses of all three antibiotics afforded almost full protection against both strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203842      PMCID: PMC284485          DOI: 10.1128/AAC.38.3.487

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Role of tolerance in cloxacillin prophylaxis of experimental Staphylococcus aureus endocarditis.

Authors:  G P Voorn; J Thompson; W H Goessens; W Schmall-Bauer; P H Broeders; M F Michel
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

2.  Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin.

Authors:  R J Faville; D E Zaske; E L Kaplan; K Crossley; L D Sabath; P G Quie
Journal:  JAMA       Date:  1978-10-27       Impact factor: 56.272

3.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

4.  Natural history of aortic valve endocarditis in rats.

Authors:  E Héraïef; M P Glauser; L R Freedman
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

5.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Significance of penicillin tolerance in vivo: prevention of experimental Streptococcus sanguis endocarditis.

Authors:  J Hess; J Dankert; D Durack
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

8.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272

9.  Vancomycin prophylaxis of experimental Streptococcus sanguis. Inhibition of bacterial adherence rather than bacterial killing.

Authors:  J P Bernard; P Francioli; M P Glauser
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Therapeutic significance of penicillin tolerance in experimental streptococcal endocarditis.

Authors:  R O Brennan; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  14 in total

1.  Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.

Authors:  Robert L Holmes; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

2.  Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.

Authors:  Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

3.  Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.

Authors:  G S Perdikaris; A Pefanis; H Giamarellou; A Nikolopoulos; E P Margaris; I Donta; A Tsitsika; P Karayiannakos
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin.

Authors:  Daniela Jabes; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Sonia Maffioli; Rosaria Rossi; Matteo Simone; Eleonora Gaspari; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

5.  In vitro development and stability of tolerance to cloxacillin and vancomycin in Staphylococcus aureus.

Authors:  G P Voorn; J Thompson; W H Goessens; W C Schmal-Bauer; P H Broeders; M F Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

6.  Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Authors:  Daniela Jabés; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

7.  Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.

Authors:  Nathalie Asseray; Cedric Jacqueline; Virginie Le Mabecque; Eric Batard; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Francesc Marco; Cristina García de la Mària; Yolanda Armero; Eurídice Amat; Dolors Soy; Asunción Moreno; Ana del Río; Manel Almela; Carlos A Mestres; José M Gatell; María Teresa Jiménez de Anta; José M Miró
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.

Authors:  Daniela Jabés; Gianpaolo Candiani; Gabriella Romanó; Cristina Brunati; Simona Riva; Marco Cavaleri
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.